ARTICLE SUMMARY:
A hotly anticipated final rule from HHS OIG intended to support value-based care partnerships doesn’t quite deliver the way device firms had hoped, though it offers some opportunities.
Device manufacturers say they are full and crucial partners in value-based healthcare arrangements, and that they should be trusted as such. But the HHS Office of Inspector General doesn’t quite see it that way.
